Page last updated: 2024-10-14

bms188797

Cross-References

ID SourceID
PubMed CID6918494
CHEMBL ID1096237
SCHEMBL ID12168431
MeSH IDM0401029

Synonyms (15)

Synonym
bms-188797
bms188797
CHEMBL1096237
4-desacetylpaclitaxel
4-desacetylpaclitaxel 4-methyl carbonate
SCHEMBL12168431
172481-83-3
0hg7s0s581 ,
unii-0hg7s0s581
bms 188797
4-desacetylpaclitaxel 4-methyl carbonate [who-dd]
DTXSID50169318
DB12619
[(1s,2s,3r,4s,7r,9s,10s,12r,15s)-12-acetyloxy-15-[(2r,3s)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-4-methoxycarbonyloxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
Q27236788

Pharmacokinetics

ExcerptReference
" Plasma pharmacokinetic mean values of maximum concentration (C(max)) and area under the curve (AUC(0-48)) increased in a dose-dependent manner within the range of doses used in this study, and in three of four patients, the DLTs correlated with AUC."( Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
Advani, R; Cho, CD; Cohen, M; Fisher, GA; Gollerkeri, A; Jambalos, C; Lum, BL; Sikic, BI, 2003
)
" Plasma pharmacokinetic data are available for 23 patients treated at 40-60 mg/m(2)."( Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days.
Cohen, M; Gallagher, ML; Gallant, G; Hahn, SM; Haller, DG; Kopit, J; O'Dwyer, PJ; Stevenson, JP; Sun, W; Vaughn, D, 2003
)
" The mean+/-SD values for clearance, distribution volume at steady state and terminal half-life during cycle 1 were 317+/-60 ml min(-1) m(-2), 258+/-96 l m(-2) and 30."( A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours.
Cohen, M; du Bois, A; Frickhofen, N; Jung, B; Loehr, A; Schaller-Kranz, T, 2006
)
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)

Compound-Compound Interactions

ExcerptReference
"We did a phase I study, in which a fixed dose of carboplatin was combined with a dose escalation schedule of BMS-188797, both administered once every 3 weeks, in patients with advanced solid malignancies."( Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies.
Cantor, A; Chiappori, AA; Cohen, MB; Dellaportas, AM; Dinwoodie, WR; Fishman, MN; Garrett, CR; Gollerki, A; Lush, RM; Mahany, JJ; Simon, GR; Sullivan, DM, 2006
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID477764Cytotoxicity against human HCT116 cells after 72 hrs2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
QSAR modeling of taxane analogues against colon cancer.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (87.50)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (55.56%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (44.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]